Enfusion Helps Hedge Funds Comply With OTC Clearing Requirements

Apr 8 2013 | 8:47am ET

Enfusion, a provider of hosted portfolio and risk management solutions for hedge funds and alternative investment firms, has recently connected its platform, Integráta, with MarkitSERV MTM to help clients comply with mandatory clearing requirements for OTC derivatives dictated by the Dodd-Frank Act.

Clients are now able to monitor trade matching and routing to the clearing houses. It also accommodates trade netting to mirror the clearing houses’ risk compression processes.

Makrem Boumlouka, executive vice president, said: "This solution gives clients fully integrated workflows for centrally cleared OTC trades. It is a logical step in our product development trajectory, as it allows us assist our clients to comply with new regulation while increasing efficiencies and reducing operational risks."

Tarek Hammoud, managing partner, added: "Our clients are moving toward more integrated processes and want to leverage on our platform’s strengths with its dual facets: technology and operations."


In Depth

Israeli Hedge Fund Harnesses Big Data

Jul 28 2014 | 8:10am ET

Apica Green is a multi-million dollar Israeli hedge fund that is based in Tel Aviv...

Lifestyle

David Yarrow On Growing His Hedge Fund And Shooting The Animals And People Of Africa - As A Photographer

Jul 23 2014 | 6:44am ET

While he’s always been a photographer, recent expeditions to Iceland, Ethiopia...

Guest Contributor

Compelling Opportunities In The Alternatives Space

Jul 29 2014 | 9:33am ET

In an environment where many asset classes seem expensive by historical standards...

 

Sponsored Content

    Northern Trust Helps Hedge Funds Navigate Derivatives Regulations

    Jul 8 2014 | 10:48am ET

    The surge in derivatives regulation is among the most complex challenges facing the financial services industry today. Northern Trust’s Joshua Satten recently spoke with FINalternatives to share insights into the challenges presented by new regulation and explore how the industry is responding. Read more…

Publisher's Note